PHILADELPHIA — The American Association for Cancer Research (AACR) recently announced the appointment of Robert D. Schreiber, PhD, and Philip D. Greenberg, MD, as editors-in-chief of Cancer Immunology Research, one of eight peer-reviewed journals published by the AACR. In their roles, Schreiber and Greenberg will set goals and determine editorial strategy for the journal.
Cancer Immunology Research publishes original articles reporting advances in cancer immunology and immunotherapies that span the spectrum of science and medicine, from basic investigations in host-tumor interactions to developmental therapeutics in model systems, early translational studies in patients, and late-stage clinical trials. The journal disseminates the latest developments in the field to cancer researchers in all disciplines, catalyzing the cross-disciplinary work needed to yield improved clinical outcomes.
“We are honored and excited about the opportunity to lead Cancer Immunology Research. Together with my co-editor-in-chief, we hope to establish the journal as the definitive voice in this rapidly expanding field,” said Schreiber.
“Cancer Immunology Research has as its goal becoming the publication forum for the breadth of investigators and clinicians engaged in or interested in immunology, particularly as it relates to cancer,” added Greenberg.
“In 2013, the AACR launched Cancer Immunology Research with Glenn Dranoff as the founding editor-in-chief to capture the most significant work in the field of cancer immunology and to highlight the relationship of cancer immunology to other areas of cancer research,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “The AACR owes much gratitude to Dr. Dranoff for his editorial vision and for the journal’s many early successes. Under the new leadership of Drs. Schreiber and Greenberg, the journal will continue its commitment to publish all aspects of cancer immunology and immunotherapy.”
Schreiber is the alumni endowed professor of pathology and immunology and director of the Center for Human Immunology and Immunotherapy Programs at Washington University School of Medicine in St. Louis. His earlier work focused on the interaction of the immune system with developing cancers and led to elucidation of the process known as cancer immunoediting.
Recently, Schreiber and colleagues used genomics approaches to identify somatic mutations in tumors that give rise to tumor-specific mutant antigens and showed that some tumor neoantigens are targets of T cells that respond to immune checkpoint antibodies. He further showed that tumor-specific neoantigens can form the basis for therapeutically effective personalized cancer vaccines.
Schreiber has received many honors, including the William B. Coley Award from the Cancer Research Institute (CRI), the Charles Rodolphe Brupbacher Prize for Cancer Research, and the AACR-CRI Lloyd J. Old Award in Cancer Immunology. He is a member of the AACR, the American Academy of Arts and Sciences, and the U.S. National Academy of Sciences. He has been a member of numerous editorial boards, including Cancer Immunology Research. He received both his bachelor’s and doctoral degrees from the State University of New York at Buffalo.
Greenberg is a professor of medicine/oncology and immunology at the University of Washington and head of the Program in Immunology at the Fred Hutchinson Cancer Research Center in Seattle. His career has focused on elucidating fundamental principles underlying a T cell’s ability to recognize and eliminate tumor cells, to distinguish cancer cells from normal cells, and to maintain function in the tumor microenvironment. His lab is developing cellular and molecular approaches to manipulate cellular immunity and overcome obstacles to effective immunotherapy, and is translating laboratory studies to the treatment of cancer patients, with a particular emphasis on adoptive therapy with genetically engineered T cells.
Greenberg’s honors include the William B. Coley Award from CRI and the Team Science Award for Career Achievements from the Society for the Immunotherapy of Cancer, among many others. He is a member of the AACR, the American Society of Clinical Investigation, the Association of American Physicians, the American College of Physicians, and the American Association for the Advancement of Science. He has served on editorial boards of multiple publications, including Cancer Immunology Research. He received his bachelor’s degree from Washington University and his medical degree from the State University of New York, Downstate Medical Center.